C81-C96
Conditions
Interventions
Group 1: myeloid diseases: every 3 months, BCL2 inhibitor plasma concentration is measured, dietary habits are recorded, side effects, concomitant medication, frailty, quality of life, disease progres
Sponsors
Universitätsmedizin Rostock, Department für Innere Medizin, Klinik und Poliklinik für Hämatologie, Hämostaseologie, Onkologie, Stammzelltherapie und Palliativmedizin
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Outpatient/inpatient treatment in the context of hematological disease Intake of BCL2 inhibitors
Exclusion criteria
Exclusion criteria: not capable of giving consent Failure to meet an inclusion criterion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Feasibility of measuring the BCL2 inhibitor concentration (i.e., Venetoclax) in blood plasma in hematological disorders? | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Is there a correlation between dietary habits and BCL2i plasma concentration? 2. Is there a correlation between concomitant medication and BCL2i plasma concentration? 3. Is there a correlation between side effects (CTCAE) and BCL2i plasma concentration? 4. Is there a correlation between the degree of frailty and BCL2i plasma concentration? a. Is there a correlation with G8 (initial/progression)? b. Is there a correlation with SPPB (initial/progression)? c. Is there a correlation with dynamometer measurement (initial/progression)? 5. Is there a correlation between quality of life (EORTC QLQ C30) and BCL2i plasma concentration? 6. Is there a correlation between pre-existing conditions (HCT-CI) and BCL2i plasma concentration? 7. Is there a correlation between disease type (AML/CLL) and BCL2i plasma concentration (initial/progression)? 8. Self-assessment of patients regarding intensive therapy vs. medical professional assessment regarding intensive therapy (e.g., transplantation)? 9. Is there a change in body composition (BIA measurement) with disease progression? 10. Does the change in body composition (BIA measurement) have an effect on the BCL2i plasma concentration? 11. Is there a correlation between changes in dietary habits and BCL2i plasma concentration? 12. Is there a correlation between changes in concomitant medication and BCL2i plasma concentration? 13. Is there a correlation between changes in disease progression and BCL2i plasma concentration? | — |
Countries
Germany
Contacts
Public ContactChristian Schmidt
Universitätsmedizin Rostock, Department für Innere Medizin, Klinik und Poliklinik für Hämatologie, Hämostaseologie, Onkologie, Stammzelltherapie und Palliativmedizin
Outcome results
None listed